Trial Profile
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Acronyms LEAP
- Sponsors GlaxoSmithKline; GSK
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2015 Planned End Date changed from 1 Mar 2020 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 19 Feb 2015 Planned End Date changed from 1 Apr 2019 to 1 Mar 2020, according to the ClinicalTrials.gov record.